A Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating Efficacy and Safety of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Fevipiprant (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 14 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 04 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 31 Oct 2014 New trial record